secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001171843-24-005393
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile
--------------------------------------------------------------------------------

- Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.
- First ordering period executed at $13.9M for 19,125 doses to be supplied by Sept 2025.
- Awarded by HHS ASPR; four optional 12-month ordering periods remain.
- Prior CDC contract of $34.7M for up to 50,000 doses concluded in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/0001171843-24-005393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/f8k_093024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer